The clinical impact of gut microbiota in chronic kidney disease

키워드

참고문헌 (83)

1. Chen TK, "Chronic kidney disease diagnosis and management : a review", JAMA, 322, pp.1294~1304 (2019)
2. 김경민, "Impact of chronic kidney disease on mortality: A nationwide cohort study", Kidney Research and Clinical Practice, 38(3), pp.382~390 (2019), 대한신장학회[DOI]
3. 진동찬, "Analysis of mortality risk from Korean hemodialysis registry data 2017", Kidney Research and Clinical Practice, 38(2), pp.169~175 (2019), 대한신장학회[DOI]
4. Rooks MG, "Gut microbiota, metabolites and host immunity", Nat Rev Immunol, 16, pp.341~352 (2016)
5. Lin L, "Role of intestinal microbiota and metabolites on gut homeostasis and human diseases", BMC Immunol, 18, pp.2~ (2017)
6. Kanbay M, "The crosstalk of gut microbiota and chronic kidney disease : role of inflammation, proteinuria, hypertension, and diabetes mellitus", Int Urol Nephrol, 50, pp.1453~1466 (2018)
7. Yang T, "The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease", Nat Rev Nephrol, 14, pp.442~456 (2018)
8. Plata C, "The gut microbiota and its relationship with chronic kidney disease", Int Urol Nephrol, 51, pp.2209~2226 (2019)
9. Mahmoodpoor F, "The impact of gut microbiota on kidney function and pathogenesis", Biomed Pharmacother, 93, pp.412~419 (2017)
10. Meijers B, "Intestinal microbiome and fitness in kidney disease", Nat Rev Nephrol, 15, pp.531~545 (2019)
11. Kang JY, "The gastrointestinal tract in uremia", Dig Dis Sci, 38, pp.257~268 (1993)
12. 임은수, "Effects of education on low-phosphate diet and phosphate binder intake to control serum phosphate among maintenance hemodialysis patients: A randomized controlled trial", Kidney Research and Clinical Practice, 37(1), pp.69~76 (2018), 대한신장학회
13. Yang J, "Intestinal barrier disruption and dysregulated mucosal immunity contribute to kidney fibrosis in chronic kidney disease", Nephrol Dial Transplant, 34, pp.419~428 (2019)
14. De Almeida Duarte JB, "Bacterial translocation in experimental uremia", Urol Res, 32, pp.266~270 (2004)
15. Yun Y, "Intestinal tract is an important organ for lowering serum uric acid in rats", PLoS One, 12, pp.e0190194~ (2017)
16. Vaziri ND, "Chronic kidney disease alters intestinal microbial flora", Kidney Int, 83, pp.308~315 (2013)
17. Wong J, "Expansion of urease-and uricase-containing, indole-and p-cresol-forming and contraction of shortchain fatty acid-producing intestinal microbiota in ESRD", Am J Nephrol, 39, pp.230~237 (2014)
18. Farhadi A, "Intestinal barrier : an interface between health and disease", J Gastroenterol Hepatol, 18, pp.479~497 (2003)
19. Steinberg D, "The DASH diet, 20years later", JAMA, 317, pp.1529~1530 (2017)
20. Chiavaroli L, "Dietary fiber effects in chronic kidney disease : a systematic review and meta-analysis of controlled feeding trials", Eur J Clin Nutr, 69, pp.761~768 (2015)
21. Lu L, "Dietary fiber intake is associated with chronic kidney disease(CKD)progression and cardiovascular risk, but not protein nutritional status, in adults with CKD", Asia Pac J Clin Nutr, 26, pp.598~605 (2017)
22. Koppe L, "The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease", Toxins(Basel), 10, pp.155~ (2018)
23. Rukavina Mikusic NL, "Gut microbiota and chronic kidney disease : evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis", Pflugers Arch, 472, pp.303~320 (2020)
24. Wu IW, "p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease", Nephrol Dial Transplant, 26, pp.938~947 (2011)
25. Miyazaki T, "Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I)collagen in uremic rat kidneys", Kidney Int Suppl, 62, pp.S15~S22 (1997)
26. Ichii O, "Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand", PLoS One, 9, pp.e108448~ (2014)
27. Han H, "p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes", J Am Heart Assoc, 4, pp.e001852~ (2015)
28. Sun CY, "Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition", PLoS One, 7, pp.e34026~ (2012)
29. Pelletier CC, "Elevation of trimethylamine-N-oxide in chronic kidney disease: contribution of decreased glomerular filtration rate", Toxins(Basel), 11, pp.635~ (2019)
30. Tang WH, "Gut microbiota-dependent trimethylamine N-oxide(TMAO)pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease", Circ Res, 116, pp.448~455 (2015)
31. Stubbs JR, "Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden", J Am Soc Nephrol, 27, pp.305~313 (2016)
32. Szeto CC, "Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients", Clin J Am Soc Nephrol, 3, pp.431~436 (2008)
33. Ramezani A, "The gut microbiome, kidney disease, and targeted interventions", J Am Soc Nephrol, 25, pp.657~670 (2014)
34. Neal MD, "Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier", J Immunol, 176, pp.3070~3079 (2006)
35. Rice JB, "Low-level endotoxin induces potent inflammatory activation of human blood vessels : inhibition by statins", Arterioscler Thromb Vasc Biol, 23, pp.1576~1582 (2003)
36. McIntyre CW, "Circulating endotoxemia : a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease", Clin J Am Soc Nephrol, 6, pp.133~141 (2011)
37. Jazani NH, "Impact of gut dysbiosis on neurohormonal pathways in chronic kidney disease", Diseases, 7, pp.21~ (2019)
38. Onal EM, "Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease", Hypertens Res, 42, pp.123~140 (2019)
39. Cosola C, "Microbiota issue in CKD : how promising are gut-targeted approaches", J Nephrol, 32, pp.27~37 (2019)
40. 백선하, "Circulating renalase predicts all-cause mortality and renal outcomes in patients with advanced chronic kidney disease", The Korean Journal of Internal Medicine, 34(4), pp.858~866 (2019), 대한내과학회[DOI]
41. Gun Ha Park, "Long-term prognosis of end-stage renal disease patients with normal myocardial perfusion as determined by single photon emission computed tomography", The Korean Journal of Internal Medicine, 33(1), pp.148~156 (2018), 대한내과학회[DOI]
42. Lin CJ, "Meta-analysis of the associations of p-cresyl sulfate(PCS)and indoxyl sulfate(IS)with cardiovascular events and all-cause mortality in patients with chronic renal failure", PLoS One, 10, pp.e0132589~ (2015)
43. Heianza Y, "Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death : a systematic review and meta-analysis of prospective studies", J Am Heart Assoc, 6, pp.e004947~ (2017)
44. 손보경, "Effectiveness of group cognitive behavioral therapy with mindfulness in end-stage renal disease hemodialysis patients", Kidney Research and Clinical Practice, 37(1), pp.77~84 (2018), 대한신장학회
45. Agusti A, "Interplay between the gut-brain axis, obesity and cognitive function", Front Neurosci, 12, pp.155~ (2018)
46. Ohtsuki S, "Role of blood-brain barrier organic anion transporter 3(OAT3)in the efflux of indoxyl sulfate, a uremic toxin : its involvement in neurotransmitter metabolite clearance from the brain", J Neurochem, 83, pp.57~66 (2002)
47. Lin YT, "Protein-bound uremic toxins are associated with cognitive function among patients undergoing maintenance hemodialysis", Sci Rep, 9, pp.20388~ (2019)
48. Watanabe I, "Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells", Circ J, 77, pp.224~230 (2013)
49. 권영은, "Fracture risk in chronic kidney disease: A Korean population-based cohort study", Kidney Research and Clinical Practice, 38(2), pp.220~228 (2019), 대한신장학회[DOI]
50. Mozar A, "Indoxyl sulphate inhibits osteoclast differentiation and function", Nephrol Dial Transplant, 27, pp.2176~2181 (2012)
51. 박정선, "Paricalcitol attenuates indoxyl sulfate-induced apoptosis through the inhibition of MAPK, Akt, and NF-kB activation in HK-2 cells", The Korean Journal of Internal Medicine, 34(1), pp.146~155 (2019), 대한내과학회[DOI]
52. Nii-Kono T, "Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells", Kidney Int, 71, pp.738~743 (2007)
53. Goto S, "Association between indoxyl sulfate and skeletal resistance in hemodialysis patients", Ther Apher Dial, 14, pp.417~423 (2010)
54. Kalmokoff M, "Temporal change in the gut community of rats fed high amylose cornstarch is driven by endogenous urea rather than strictly on carbohydrate availability", J Appl Microbiol, 114, pp.1516~1528 (2013)
55. Kieffer DA, "Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats", Am J Physiol Renal Physiol, 310, pp.F857~F871 (2016)
56. Vaziri ND, "High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease", PLoS One, 9, pp.e114881~ (2014)
57. Krishnamurthy VM, "High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease", Kidney Int, 81, pp.300~306 (2012)
58. Gibson GR, "Dietary modulation of the human colonic microbiota : introducing the concept of prebiotics", J Nutr, 125, pp.1401~1412 (1995)
59. Gibson GR, "Dietary modulation of the human colonic microbiota : updating the concept of prebiotics", Nutr Res Rev, 17, pp.259~275 (2004)
60. Meijers BK, "p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin", Nephrol Dial Transplant, 25, pp.219~224 (2010)
61. Sueyoshi M, "Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats", Clin Exp Nephrol, 23, pp.908~919 (2019)
62. Rastall RA, "Modulation of the microbial ecology of the human colon by probiotics, prebiotics and synbiotics to enhance human health : an overview of enabling science and potential applications", FEMS Microbiol Ecol, 52, pp.145~152 (2005)
63. Ranganathan N, "Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease", Adv Ther, 27, pp.634~647 (2010)
64. Ranganathan N, "Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease : a 6-month pilot scale trial in Canada", Curr Med Res Opin, 25, pp.1919~1930 (2009)
65. Guida B, "Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure : a randomized clinical trial", Nutr Metab Cardiovasc Dis, 24, pp.1043~1049 (2014)
66. Viramontes-Horner D, "Effect of a symbiotic gel(Lactobacillus acidophilus + Bifidobacterium lactis + inulin)on presence and severity of gastrointestinal symptoms in hemodialysis patients", J Ren Nutr, 25, pp.284~291 (2015)
67. Esgalhado M, "Could resistant starch supplementation improve inflammatory and oxidative stress biomarkers and uremic toxins levels in hemodialysis patients? : a pilot randomized controlled trial", Food Funct, 9, pp.6508~6516 (2018)
68. Poesen R, "The influence of prebiotic arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease : a randomized controlled trial", PLoS One, 11, pp.e0153893~ (2016)
69. Ramos CI, "Effect of prebiotic(fructooligosaccharide)on uremic toxins of chronic kidney disease patients : a randomized controlled trial", Nephrol Dial Transplant, 34, pp.1876~1884 (2019)
70. Laffin MR, "Amylose resistant starch (HAM-RS2) supplementation increases the proportion of Faecalibacterium bacteria in end-stage renal disease patients: microbial analysis from a randomized placebo-controlled trial", Hemodial Int, 23, pp.343~347 (2019)
71. Eidi F, "Effect of Lactobacillus rhamnosus on serum uremic toxins (phenol and p-cresol) in hemodialysis patients: a double blind randomized clinical trial", Clin Nutr ESPEN, 28, pp.158~164 (2018)
72. Mafi A, "Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy : a randomized, double-blind, placebo-controlled trial", Food Funct, 9, pp.4763~4770 (2018)
73. Borges NA, "Effects of probiotic supplementation on trimethylamine-N-oxide plasma levels in hemodialysis patients : a pilot study", Probiotics Antimicrob Proteins, 11, pp.648~654 (2019)
74. Rossi M, "Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY):a randomized trial", Clin J Am Soc Nephrol, 11, pp.223~231 (2016)
75. Guida B, "Effect of a shortcourse treatment with synbiotics on plasma p-cresol concentration in kidney transplant recipients", J Am Coll Nutr, 36, pp.586~591 (2017)
76. Dehghani H, "Synbiotic supplementations for azotemia in patients with chronic kidney disease : a randomized controlled trial", Iran J Kidney Dis, 10, pp.351~357 (2016)
77. Thongprayoon C, "High mortality risk in chronic kidney disease and end stage kidney disease patients with clostridium difficile infection : a systematic review and meta-analysis", J Nat Sci, 1, pp.e85~ (2015)
78. Sun Chul Kim, "Advanced chronic kidney disease: a strong risk factor for Clostridium difficile infection", The Korean Journal of Internal Medicine, 31(1), pp.125~133 (2016), 대한내과학회[DOI]
79. Liu WC, "Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120", Toxins(Basel), 10, pp.367~ (2018)
80. Sato E, "Effects of the oral adsorbent AST-120 on fecal p-cresol and indole levels and on the gut microbiota composition", Biochem Biophys Res Commun, 525, pp.773~779 (2020)
81. 차란희, "Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post-hoc analysis of the Kremezin Study against renal disease progression in Korea", Kidney Research and Clinical Practice, 36(1), pp.68~78 (2017), 대한신장학회
82. Chen YC, "Effects and safety of an oral adsorbent on chronic kidney disease progression : a systematic review and meta-analysis", J Clin Med, 8, pp.1718~ (2019)
83. Rodriguez-Osorio L, "Use of sevelamer in chronic kidney disease : beyond phosphorus control", Nefrologia, 35, pp.207~217 (2015)

관련 논문AI추천